A computer-implemented method for evaluating the risk of mortality within one year due to cardiovascular disease for a subject having or diagnosed as having heart failure, the method comprising: (a) determining a multimarker mortality risk score for the subject using the following algorithm: age of a subject + level of soluble ST2 in a sample from the subject + natural logarithm of systolic blood pressure in the subject (ln_SBP) + history of cardiovascular disease in the subject + natural logarithm of level of N-terminal pro-brain natriuretic peptide in a sample from the subject (In_NTpro-BNP); and (b) comparing the multimarker mortality risk score to a reference multimarker mortality risk score; wherein the presence of a multimarker mortality risk score that is at or above the reference multimarker mortality risk score indicates that the subject has an increased risk of mortality due to CVD within one year, and the presence of a multimarker mortality risk score that is below the reference multimarker mortality risk score indicates that the subject has a decreased risk of mortality due to CVD within one year; and wherein: age is measured in years; ST2 is measured in ng/mL and compared to a threshold of ST2 of 35 ng/mL, where the presence of a level of ST2 at or above the threshold is scored as "1" and the presence of a level of ST2 below the threshold is scored as "0"; SBP is measured in mmHg; CAD is either scored as "0" in the absence of CAD or scored as "1" in the presence of CAD; and NTpro-BNP is measured in pg/mL. (a) determining a multimarker mortality risk score for the subject using the following algorithm: age of a subject + level of soluble ST2 in a sample from the subject + natural logarithm of systolic blood pressure in the subject (ln_SBP) + history of cardiovascular disease in the subject + natural logarithm of level of N-terminal pro-brain natriuretic peptide in a sample from the subject (In_NTpro-BNP); and (b) comparing the multimarker mortality risk score to a reference multimarker mortality risk score; wherein the presence of a multimarker mortality risk score that is at or above the reference multimarker mortality risk score indicates that the subject has an increased risk of mortality due to CVD within one year, and the presence of a multimarker mortality risk score that is below the reference multimarker mortality risk score indicates that the subject has a decreased risk of mortality due to CVD within one year; and wherein: age is measured in years; ST2 is measured in ng/mL and compared to a threshold of ST2 of 35 ng/mL, where the presence of a level of ST2 at or above the threshold is scored as "1" and the presence of a level of ST2 below the threshold is scored as "0"; SBP is measured in mmHg; CAD is either scored as "0" in the absence of CAD or scored as "1" in the presence of CAD; and NTpro-BNP is measured in pg/mL. wherein the presence of a multimarker mortality risk score that is at or above the reference multimarker mortality risk score indicates that the subject has an increased risk of mortality due to CVD within one year, and the presence of a multimarker mortality risk score that is below the reference multimarker mortality risk score indicates that the subject has a decreased risk of mortality due to CVD within one year; and wherein: age is measured in years; ST2 is measured in ng/mL and compared to a threshold of ST2 of 35 ng/mL, where the presence of a level of ST2 at or above the threshold is scored as "1" and the presence of a level of ST2 below the threshold is scored as "0"; SBP is measured in mmHg; CAD is either scored as "0" in the absence of CAD or scored as "1" in the presence of CAD; and NTpro-BNP is measured in pg/mL. age is measured in years; ST2 is measured in ng/mL and compared to a threshold of ST2 of 35 ng/mL, where the presence of a level of ST2 at or above the threshold is scored as "1" and the presence of a level of ST2 below the threshold is scored as "0"; SBP is measured in mmHg; CAD is either scored as "0" in the absence of CAD or scored as "1" in the presence of CAD; and NTpro-BNP is measured in pg/mL.